Abcellera Biologics Inc (NASDAQ: ABCL) — Company Overview, News & Financial Data
Abcellera Biologics develops next-generation antibody therapies utilizing AI and deep genomics for various diseases.
Abcellera Biologics Inc
Abcellera Biologics (NASDAQ:ABCL) is a biotech firm focused on discovering and developing next-generation antibody therapies to address challenging diseases. By leveraging a proprietary technology that combines artificial intelligence, deep genomics, and a massively parallel microfluidic lab-on-a-chip platform, Abcellera aims to revolutionize the speed and efficiency of therapeutic antibody discovery. The company's projects span a range of therapeutic areas, including infectious diseases, immuno-oncology, and neurodegeneration, with the objective to rapidly transform novel molecular insights into full-spectrum antibody therapies. Abcellera’s collaborative and partnership-driven approach enables it to work alongside some of the world’s leading biopharmaceutical companies, amplifying its impact across the healthcare ecosystem.
Snapshot
Operations
Products and/or services of Abcellera Biologics Inc
- Development of a monoclonal antibody therapy for COVID-19 in collaboration with Eli Lilly, providing a significant tool in combating the pandemic.
- Partnerships with major pharmaceutical companies for antibody discovery utilizing their proprietary technology, expanding therapeutic options across various diseases.
- Creation of a deep learning-powered drug discovery platform that accelerates the identification of antibody candidates, enhancing the speed and efficiency of preclinical drug development.
- Offering an end-to-end solution for antibody discovery, including target validation, screening, and preclinical development, supporting partners through the drug development process.
- Collaboration with the Bill & Melinda Gates Foundation to identify antibody therapies for malaria and tuberculosis, aiming to address global health challenges.
- Development of a proprietary microfluidics technology for single B cell screening, enabling the rapid and efficient discovery of high-quality antibodies against challenging targets.
Abcellera Biologics Inc executive team
- Carl L.G. HansenCEO, President & Chairperson
- Andrew BoothChief Financial Officer
- Veronique LecaultCTO & Director
- Tryn T. StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer
- Andrew KnowlesVice President of Operations
- Martin HoganSenior Director of Strategic Finance & IR
- Tiffany ChiuVice President of Communications
Latest news about Abcellera Biologics Inc
Key financials
Reported results for Abcellera Biologics Inc, in USD.
- Market cap
- 4.2B
- Revenue (TTM)
- 66.2M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.5
- Dividend yield
- —
- Profit margin
- -248.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 75.1M | -217.1M | -146.4M | |
| 28.8M | -314.8M | -162.9M | |
| 38M | -237.2M | -146.4M | |
| 485.4M | 216.5M | 158.5M |